Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Munir Alam

Showing results (161-170 of 206) with videos related to

Pageof 21
Sort By:
Ebiomedicine|September 11, 2016
Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization SensitivityTodd Bradley, Ashley Trama, Nancy Tumba, et al.
Nature|September 5, 2014
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interfaceJinghe Huang, Byong H Kang, Marie Pancera, et al.
The Journal of Experimental Medicine|April 7, 2010
Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokinesM Anthony Moody, Hua-Xin Liao, S Munir Alam, et al.
Cell|November 19, 2022
A Zika virus-specific IgM elicited in pregnancy exhibits ultrapotent neutralizationTulika Singh, Kwan-Ki Hwang, Andrew S Miller, et al.
Plos Pathogens|February 25, 2017
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trialDavid Easterhoff, M Anthony Moody, Daniela Fera, et al.
Journal of Virology|May 15, 2015
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchLindsay Wieczorek, Shelly J Krebs, Vaniambadi Kalyanaraman, et al.
Science Translational Medicine|September 7, 2022
Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infectionKevin O Saunders, Robert J Edwards, Kedamawit Tilahun, et al.
Science Translational Medicine|March 21, 2014
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccinationNicole L Yates, Hua-Xin Liao, Youyi Fong, et al.
Journal of Virology|November 24, 2012
Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletionS Munir Alam, Hua-Xin Liao, Georgia D Tomaras, et al.
Immunity|December 20, 2014
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conservedKevin Wiehe, David Easterhoff, Kan Luo, et al.
Pageof 21

Showing results (161-170 of 206) with videos related to

Sort By:
Pageof 21
Ebiomedicine|September 11, 2016
Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization SensitivityTodd Bradley, Ashley Trama, Nancy Tumba, et al.
Nature|September 5, 2014
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interfaceJinghe Huang, Byong H Kang, Marie Pancera, et al.
The Journal of Experimental Medicine|April 7, 2010
Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokinesM Anthony Moody, Hua-Xin Liao, S Munir Alam, et al.
Cell|November 19, 2022
A Zika virus-specific IgM elicited in pregnancy exhibits ultrapotent neutralizationTulika Singh, Kwan-Ki Hwang, Andrew S Miller, et al.
Plos Pathogens|February 25, 2017
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trialDavid Easterhoff, M Anthony Moody, Daniela Fera, et al.
Journal of Virology|May 15, 2015
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchLindsay Wieczorek, Shelly J Krebs, Vaniambadi Kalyanaraman, et al.
Science Translational Medicine|September 7, 2022
Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infectionKevin O Saunders, Robert J Edwards, Kedamawit Tilahun, et al.
Science Translational Medicine|March 21, 2014
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccinationNicole L Yates, Hua-Xin Liao, Youyi Fong, et al.
Journal of Virology|November 24, 2012
Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletionS Munir Alam, Hua-Xin Liao, Georgia D Tomaras, et al.
Immunity|December 20, 2014
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conservedKevin Wiehe, David Easterhoff, Kan Luo, et al.
Pageof 21